Depei Wu

TL;DR: Unmanipulated haploidentical HSCT achieves outcomes similar to those of ISD HSCT for AML patients in CR1, and was demonstrated to be a valid alternative as postremission treatment of intermediate- or high-risk AMl patients inCR1 lacking an identical donor.

TL;DR: The safety of CD33-CAR NK cells in patients with relapsed and refractory AML was tested and, at doses up to 5 × 109 cells per patient, no significant adverse effects were observed.

TL;DR: This study identified a distinct glucose metabolism signature with 400 AML patients and 446 healthy controls and generated a prognosis risk score (PRS) with 6 metabolite markers for each patient using principal component analysis, providing strong evidence for the use of serum metabolites and metabolic pathways as novel prognostic markers and potential therapeutic targets for AML.

TL;DR: The consensus on routine practices of all-HSCT in China is summarized and the recommendations of indications, conditioning regimen, and donor selection are focused on.

TL;DR: The common COVID-19 abnormal hematological indexes on admission included hyperfibrinogenemia, lymphopenia, the elevation of D-dimer, and leuk Openia, which were significantly different between the mild/moderate and severe CO VID-19 groups.